Literature DB >> 1641061

Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B.

J P Sullivan1, K F Tipton.   

Abstract

The kinetics of the interactions of MPTP and its N-des-methyl-derivative (PTP) have been studied. Both were mechanism-based inhibitors as well as substrates for the enzyme. Analysis of the reaction progress-curves for the formation of the corresponding dihydropyridine derivatives allowed the kinetic parameters for the process and the partition ratio, which corresponds to the number of mol. of product formed per mol. of enzyme inactivated, to be determined for both compounds. The conversion of MPTP to its corresponding pyridinium-ion derivative through the action of MAO-B is known to be essential for its neurotoxicity. PTP has been reported not to be neurotoxic, although it appears to be a relatively good substrate for MAO-B as well as acting as a mechanism-based inhibitor. Studies of the changes in absorbance spectra during the MAO-B catalysed oxidation were consistent with the formation of the corresponding pyridinium-ion derivative (MPP+), which is known to be the effective neurotoxin, as the end-product when MPTP was oxidized. In contrast the oxidation of PTP appeared to stop at the dihydropyridine stage with no significant further oxidation to the corresponding pyridine-derivative.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1641061     DOI: 10.1007/bf00969014

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  27 in total

1.  Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.

Authors:  M N Hassan; J H Thakar; J D Grimes
Journal:  Adv Neurol       Date:  1990

Review 2.  The neurotoxicity of MPTP and the relevance to Parkinson's disease.

Authors:  J M McCrodden; K F Tipton; J P Sullivan
Journal:  Pharmacol Toxicol       Date:  1990-07

3.  The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson's disease.

Authors:  H Kinemuchi; C J Fowler; K F Tipton
Journal:  Neurochem Int       Date:  1987       Impact factor: 3.921

Review 4.  MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.

Authors:  S H Snyder; R J D'Amato
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

5.  Monoamine oxidase from beef liver mitochondria: simplified isolation procedure, properties, and determination of its cysteinyl flavin content.

Authors:  J I Salach
Journal:  Arch Biochem Biophys       Date:  1979-01       Impact factor: 4.013

6.  Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  T P Singer; N Castagnoli; R R Ramsay; A J Trevor
Journal:  J Neurochem       Date:  1987-07       Impact factor: 5.372

7.  Predicting Parkinson's disease.

Authors:  S H Snyder; R J D'Amato
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

8.  Kinetics of suicide substrates. Practical procedures for determining parameters.

Authors:  S G Waley
Journal:  Biochem J       Date:  1985-05-01       Impact factor: 3.857

9.  Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  K F Tipton; J M McCrodden; M B Youdim
Journal:  Biochem J       Date:  1986-12-01       Impact factor: 3.857

10.  The interactions of monoamine oxidase with some derivatives of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  J P Sullivan; K F Tipton
Journal:  J Neural Transm Suppl       Date:  1990
View more
  2 in total

Review 1.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 2.  90 years of monoamine oxidase: some progress and some confusion.

Authors:  Keith F Tipton
Journal:  J Neural Transm (Vienna)       Date:  2018-04-10       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.